1. Home
  2. KIM vs VTRS Comparison

KIM vs VTRS Comparison

Compare KIM & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimco Realty Corporation (HC)

KIM

Kimco Realty Corporation (HC)

HOLD

Current Price

$20.59

Market Cap

13.6B

Sector

Real Estate

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$12.61

Market Cap

14.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KIM
VTRS
Founded
1958
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6B
14.2B
IPO Year
1991
N/A

Fundamental Metrics

Financial Performance
Metric
KIM
VTRS
Price
$20.59
$12.61
Analyst Decision
Buy
Hold
Analyst Count
12
6
Target Price
$24.17
$11.50
AVG Volume (30 Days)
4.5M
8.6M
Earning Date
02-12-2026
02-26-2026
Dividend Yield
5.12%
3.85%
EPS Growth
57.13
N/A
EPS
0.83
N/A
Revenue
$2,123,057,000.00
$14,124,400,000.00
Revenue This Year
$5.60
N/A
Revenue Next Year
$3.39
$1.18
P/E Ratio
$24.42
N/A
Revenue Growth
8.14
N/A
52 Week Low
$17.93
$6.85
52 Week High
$23.65
$12.68

Technical Indicators

Market Signals
Indicator
KIM
VTRS
Relative Strength Index (RSI) 56.08 75.62
Support Level $19.97 $12.19
Resistance Level $20.46 $12.68
Average True Range (ATR) 0.28 0.27
MACD 0.05 0.00
Stochastic Oscillator 84.38 92.68

Price Performance

Historical Comparison
KIM
VTRS

About KIM Kimco Realty Corporation (HC)

One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: